scholarly journals The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Acral Warts: A Retrospective Study

2020 ◽  
Vol 49 (10) ◽  
pp. 749-755
Author(s):  
Ling Yee Kuan ◽  
Sze Hon Chua ◽  
Jiun Yit Pan ◽  
Yik Weng Yew ◽  
Wee Ping Tan
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Adverse Reactions ◽  
Quadrivalent Vaccine ◽  
Adjunctive Treatment ◽  
Human Papillomavirus Vaccine ◽  
Complete Clearance ◽  
Quadrivalent Hpv Vaccine ◽  
Papillomavirus Vaccine

Introduction: The human papillomavirus (HPV) vaccine has been reported to lead to clinical clearance of lesions when used as an off-label treatment for recalcitrant extragenital warts. The aim of the study is to evaluate the therapeutic and adverse effects of HPV vaccine as an adjunctive therapy for treatment-resistant acral warts. Methods: Patients with persistent warts despite first and second line therapies, and subsequently receiving the quadrivalent HPV vaccine between July 2013 and June 2016 as an adjunctive treatment for recalcitrant warts at the National Skin Centre, were included. Results: Twenty-six patients with a median age of 34 years (range 8 to 77 years) were treated with the HPV vaccine. Nineteen (73.1%) patients completed 3 doses of the vaccine, of whom 5 (26%) achieved complete clearance, 8 (42%) had partial clearance and 6 (32%) did not respond to the vaccine. Among the 4 patients who received 2 doses of the vaccine, 3 (75%) had complete clearance whereas 1 (25%) had partial improvement of their warts. None of the patients reported adverse reactions. Conclusion: Our study suggests a potential adjunctive role of the HPV vaccine in the treatment of acral warts recalcitrant to conventional therapy. Keywords: Acral warts, HPV vaccine, quadrivalent vaccine, recalcitrant warts

scholarly journals Australia’s Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 921
Author(s):  
Zheng Quan Toh ◽  
Chau Quang ◽  
Joseph A. Tooma ◽  
Suzanne M. Garland ◽  
Kim Mulholland ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Asia Pacific ◽  
Pneumococcal Vaccines ◽  
Human Papillomavirus Vaccine ◽  
Middle Income ◽  
National Immunisation ◽  
Middle Income Countries ◽  
Papillomavirus Vaccine

Australian researchers have made substantial contributions to the field of vaccinology over many decades. Two examples of this contribution relate to pneumococcal vaccines and the human papillomavirus (HPV) vaccine, with a focus on improving access to these vaccines in low- and lower-middle-income countries (LLMICs). Many LLMICs considering introducing one or both of these vaccines into their National Immunisation Programs face significant barriers such as cost, logistics associated with vaccine delivery. These countries also often lack the resources and expertise to undertake the necessary studies to evaluate vaccine performance. This review summarizes the role of Australia in the development and/or evaluation of pneumococcal vaccines and the HPV vaccine, including the use of alternative vaccine strategies among countries situated in the Asia-Pacific region. The outcomes of these research programs have had significant global health impacts, highlighting the importance of these vaccines in preventing pneumococcal disease as well as HPV-associated diseases.

Vaccine Hesitancy and Differential Susceptibility to Media Coverage: A Critical Documentary Led to Substantial Reductions in Human Papillomavirus Vaccine Uptake in Denmark

2021 ◽  
pp. 0272989X2110035
Author(s):  
Maria Knoth Humlum ◽  
Niels Skipper ◽  
Peter Rønø Thingholm
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Media Coverage ◽  
Differential Susceptibility ◽  
Vaccine Uptake ◽  
Vaccine Hesitancy ◽  
Human Papillomavirus Vaccine ◽  
Policy Makers ◽  
Quasi Experimental ◽  
Papillomavirus Vaccine

Objectives To investigate whether negative media coverage of the human papillomavirus (HPV) vaccine led to a decrease in the uptake of the first dose of the HPV vaccine (HPV1) in Denmark and, importantly, whether some groups of individuals were more susceptible to negative media coverage. Methods We measured HPV vaccine uptake of 12-year-old girls born in 2001 to 2004 using Danish administrative data. A quasi-experimental design was employed to assess whether a documentary that was critical of the HPV vaccine and aired in March 2015 affected HPV uptake. Results The documentary led to a quick and substantial decrease in the monthly propensity to vaccinate, which dropped 3 percentage points—or about 50%—in response to the documentary. Responses differed substantially across subgroups, and girls from families with high socioeconomic status (SES) were more susceptible to the negative media coverage. Conclusions Susceptibility to negative media coverage varied substantially across subgroups, highlighting the need for policy makers to appropriately target and differentiate initiatives to improve vaccine compliance rates.

Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007–2011)

2014 ◽  
Vol 81 (5) ◽  
pp. 303-309 ◽  
Author(s):  
M.A. Rodríguez-Galán ◽  
S. Pérez-Vilar ◽  
J. Díez-Domingo ◽  
J. Tuells ◽  
J. Gomar-Fayos ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Adverse Reactions ◽  
Human Papillomavirus Vaccine ◽  
Papillomavirus Vaccine

A Case of Myopericarditis and the HPV vaccine

2021 ◽  
Vol 9 (12) ◽  
Author(s):  
Angela Pegram ◽  
Tara Bush
Keyword(s):  
Human Papillomavirus ◽  
Social History ◽  
Hpv Vaccine ◽  
Package Insert ◽  
Human Papillomavirus Vaccine ◽  
T Wave ◽  
Dose Number ◽  
Males And Females ◽  
Artery Disease ◽  
Papillomavirus Vaccine

Introduction: Human Papillomavirus (HPV) is the underlying etiology of numerous cancers and genital warts in both males and females. Vaccines were developed against HPV to prevent transmission and arrest development of cancers caused by the virus. Gardasil 9â is the newest vaccine, covering 9 serotypes of HPV and is recommended by the CDC for both males and females over 9 years of age in a series of vaccinations. Myopericarditis (including myocarditis and pericarditis) is not reported as an adverse reaction in the Gardasil 9â package insert. Case Report A healthy 18-year-old male with no significant past medical or social history received dose number 3 of HPV vaccine at his physician’s office. Within 24 hours, he developed chills and a fever (normal HPV reactions) and then recovered without sequelae within 48 hours. Three days later, he developed crushing chest pain, with arm tingling and jaw pain. He was triaged directly to the emergency room where he had troponins of greater than 11000 and T wave inversions on his EKG. Other diagnostic tests and labs showed normal heart anatomy and no early coronary artery disease. He was diagnosed with myopericarditis by cardiology. He was treated and recovered fully within 3 months. Discussion Using the WHO tool for adverse vaccine reactions, this case has a consistent causal relationship with vaccination. This is the eleventh case of myopericarditis reported to the Vaccine Adverse Effects Reporting system for the HPV vaccine. Conclusion Although rare, myopericarditis should be considered as a possible adverse effect from the human papillomavirus vaccine.

scholarly journals 962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S29-S29
Author(s):  
Julia Gargano ◽  
Rayleen Lewis ◽  
Hillary Hunt ◽  
Nancy McClung ◽  
Nancy M Bennett ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
The United States ◽  
Adenocarcinoma In Situ ◽  
Human Papillomavirus Vaccine ◽  
Impact Monitoring ◽  
Vaccine Impact ◽  
Race Ethnicity ◽  
Papillomavirus Vaccine

Abstract Background Since human papillomavirus (HPV) vaccine introduction in the United States in 2006, cervical pre-cancer incidence has declined in young women, but pre-cancer trends have not been reported by race/ethnicity. We evaluated trends in cervical pre-cancers from 2008 to 2016 in non-Hispanic (NH) white, NH black, NH Asian, and Hispanic women identified through active population-based surveillance in the 5-site Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT). Methods We analyzed data on cervical intraepithelial neoplasia (CIN) grades 2–3 and adenocarcinoma in situ (CIN2+) cases aged 20–39 years. Annual CIN2+ rates per 100,000 women were calculated stratified by race/ethnicity in 5-year age groups, using multiple imputation to account for 10% missing race/ethnicity data. Rates were also calculated using estimated numbers screened for cervical cancer to control for known declines in screening. Trends, evaluated using JoinPoint software, are presented as average annual percentage changes (AAPC) with 95% confidence intervals (CI). Results A total of 18,222 CIN2+ cases (62% NH white, 16% NH black, 16% Hispanic, 6% Asian) were reported from 2008 to 2016. CIN2+ rates among 20–24 year-olds declined significantly in all groups: NH white, AAPC: −14.2 (95% CI: −16.3, −12.1); NH black, AAPC: −15.5 (−19.5, −11.4); Asian, AAPC: −14.8 (−20.5, −8.8); Hispanic, AAPC: −14.3 (−17.9, −10.5). In 25–29 year olds, a significant decline was observed for NH whites only (AAPC: −2.4, [−4.0, −0.8]). No declines were seen in 30–34 or 35–39 year olds. Among screened 20–24 year-olds, significant but smaller declines were observed (AAPC: −9.8 to −8.4); no declines were observed in screened 25–29 year olds or older groups. Conclusion In this evaluation of CIN2+ trends by race/ethnicity during the HPV vaccine era, the significant declines in 20–24 year olds across all groups, including among screened women, is consistent with equitable vaccine impact on CIN2+. Disclosures All Authors: No reported Disclosures.

Bioethics Human Papillomavirus and HPV Vaccine

2019 ◽  
Author(s):  
Christine Shanahan Davies
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Ethical Issues ◽  
Social Issues ◽  
Scientific Evidence ◽  
Ethical Question ◽  
Clinical Aspects ◽  
Human Papillomavirus Vaccine ◽  
Family Nurse Practitioner ◽  
Papillomavirus Vaccine

This paper will discuss what the Human Papillomavirus (HPV) is. Ethical questions posed are “Should the HPV (Human Papillomavirus) vaccine be required? If yes at what age and should it be required for both boys and girls? During the paper another ethical question that will be discussed is, “On what basis should parents be permitted to refuse and be exempt from the mandate”? An analysis of the Human papillomavirus will explain what is HPV, how it is passed between people, any symptoms that could occur, and information about treatment, vaccines, and prevention. The role and responsibilities of the Family Nurse Practitioner, clinical aspects, scientific evidence, conflicts, social issues, contextual facts and stakeholders will all be discussed. In addition bioethical principles autonomy, informed consent, beneficence, non-malfeasance, and justice will be discussed that are relevant and applicable to the ethical issues associated with the Human papillomavirus and HPV vaccine.

Sign in / Sign up

Export Citation Format

Share Document